OSSTEC ASCENT cementless partial knee replacement implant developed using 3D-printing and biomimetic fixation technology.
London-based medical technology startup OSSTEC has secured $8 million in funding led by EMBRYO Ventures. The investment will support US regulatory clearance, planned clinical procedures and further development of its cementless joint replacement technology.

OSSTEC, a London-based medical technology company developing 3D-printed joint replacement implants, has raised $8 million in a funding round led by EMBRYO Ventures. The round included participation from Neovate Capital, New Wave Ventures, Oxford Technology Innovation Finance and Empirical Ventures.

The company plans to use the investment to advance its ASCENT cementless partial knee replacement system towards US regulatory clearance and initial clinical procedures. The funding will also support surgeon training, product development and the expansion of its US operations.

Founded in 2021 by Dr. Max Munford as a spinout from Imperial College London, OSSTEC develops orthopaedic implants using additive manufacturing and biomimetic fixation technology. The company’s approach is based on research into implant fixation and bone integration, with the aim of enabling joint replacements without the use of bone cement.

Its lead product, ASCENT, is a 3D-printed, cementless, fixed-bearing partial knee replacement system. It is designed to support biological fixation by allowing bone to integrate with the implant’s engineered surface. The system is accompanied by CLARITY surgical instrumentation, developed to support the implantation procedure.

The new financing will help OSSTEC pursue US Food and Drug Administration (FDA) clearance for ASCENT and CLARITY, with first-in-human procedures in the United States planned for the first half of 2027. Both products remain uncleared by the FDA and are not currently available for sale in the US.

OSSTEC is also developing additional applications for its cementless fixation platform beyond partial knee replacement. The company is evaluating potential integration with robotic surgery systems as part of its broader product development activities.

The latest investment follows earlier fundraising rounds, including £1.2 million raised in 2023 and £2.5 million secured in 2025. The 2025 financing supported the company’s initial expansion into the United States, where it has since established operations and developed relationships with orthopaedic surgeons.

The $8 million round will support OSSTEC’s transition towards initial clinical use of its ASCENT system while advancing its pipeline of cementless joint replacement technologies.

Get the latest startup funding news in your inbox.

We don’t spam! Read our privacy policy for more info.

Share